MCC950

MCC950 was described in 2015 as a potent, selective small-molecule NLRP3 inhibitor that blocked canonical and noncanonical activation at nanomolar concentrations, spared the AIM2, NLRC4, and NLRP1 inflammasomes, reduced interleukin-1 beta in vivo, attenuated experimental autoimmune encephalomyelitis, and rescued neonatal lethality in a cryopyrin-associated periodic syndrome mouse model. A later review summarized its drug targets, metabolism, and toxicity, noting broad preclinical efficacy across autoimmune, cardiovascular, and metabolic disease and cautioning that earlier clinical development as CP-456773 for rheumatoid arthritis was limited by hepatotoxicity.

In a nonalcoholic steatohepatitis model, MCC950 normalized hepatic caspase-1 and interleukin-1 beta, reduced liver inflammation, and lessened fibrosis, apparently by blocking cholesterol-crystal-mediated NLRP3 activation in myeloid cells. In diabetic stroke models it improved cognitive outcome and neurovascular remodeling and preserved brain-derived neurotrophic factor secretion under hypoxic, diabetes-mimicking conditions.

It also attenuated atherosclerosis by limiting macrophage pyroptosis and NLRP3 assembly, and suppressed inducible atrial fibrillation driven by cardiomyocyte NLRP3 signaling. Together these studies establish MCC950 as a mechanistic benchmark for NLRP3 inhibition while underscoring that its own translation to humans has been constrained by liver safety.

MCC950 is a laboratory reagent, not a human medicine. Its earlier incarnation as Pfizer's CP-456773 entered clinical testing for rheumatoid arthritis decades ago but development was halted after signals of liver toxicity, and no safe human dose has been established. As an innate-immune suppressant it could in principle raise infection risk. It should be regarded as a research tool only and not consumed.

The molecule was first synthesized at Pfizer in the 1990s as CP-456773, a cytokine release inhibitory drug (CRID3), before its precise target was known. In 2015, Coll and colleagues identified it as a selective NLRP3 inhibitor and renamed it MCC950, after which it became the standard pharmacological tool for interrogating NLRP3 across hundreds of preclinical studies.

MCC950 is the reference NLRP3 inhibitor in immunology research and is cited across a vast preclinical literature. It is not a supplement or clinical drug; its reputation is as a benchmark tool compound, tempered by the hepatotoxicity that ended its early human development and by newer inhibitors designed to improve on it.